Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT01744626 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia Lymphocytic Chronic B-Cell

Interventions

DRUG: CC-292
DRUG: Rituximab

Sponsor

Celgene Corporation